Close menu




January 22nd, 2025 | 07:00 CET

Evotec, Vidac Pharma, BioNTech – Profiting from the fight against cancer

  • Biotechnology
  • Biotech
  • Pharma
Photo credits: pixabay.com

It has been clear for some time that cancer can affect anyone, and not just since King Charles and Princess Kate made their battles with cancer public. The market is growing, and today, revenues in this area are already in the billions. This is driven by an aging population and increasingly unhealthy lifestyles. The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a genuine blockbuster. In 2023, around USD 223 billion was spent on cancer drugs worldwide. We are looking at three companies striving to cure cancer and claim their share of this lucrative market.

time to read: 4 minutes | Author: Armin Schulz
ISIN: EVOTEC SE INH O.N. | DE0005664809 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Evotec – Broadly positioned

    Evotec's business concept is based on strategic partnerships. To this end, the Company provides its partners with scientific expertise and technological innovations. The Hamburg-based company uses a multimodal platform that integrates various technologies, including iPSC and PanOmics. iPSC facilitates disease modelling at the cellular level, while PanOmics improves the understanding of disease mechanisms. The integration of artificial intelligence accelerates development times and streamlines the overall process. This approach promises a competitive advantage, particularly in the field of modern oncology.

    In recent years, Evotec has entered into strategic partnerships, such as with Dewpoint Therapeutics, to jointly tackle difficult-to-treat cancers. The co-ownership strategy shares the risks, costs, and ownership between the parties. This approach has enabled Evotec to significantly expand its co-owned pipeline in recent years in the areas of small modular assets, biological agents, and cell and gene therapy. On December 11, the first three projects to combat cardiometabolic diseases were selected together with Novo Nordisk.

    Although there were positive developments in terms of partnerships last year, it was still a challenging year for shareholders. First, there was an unexpected change in CEO, and then the figures also left something to be desired. The new CEO, Dr Christian Wojczewski, wants to review the Company's strategy and has already initiated cost reductions. The Company plans to announce its future course of action by April at the latest, based on the results it has developed. Before that, on March 27, Evotec will present its Q4 figures. With a current share price of EUR 7.93, the Company could continue to be attractive as a takeover target.

    Vidac Pharma – Strong Phase 2a study results

    Vidac Pharma has established itself as a promising player in cancer research. Led by CEO Prof. Dr. Max Herzberg, a highly respected scientist and entrepreneur, the Company has set itself the goal of developing oncological and oncodermatological therapies. The Company is focusing on a new type of cancer treatment. The drugs are designed to reverse the abnormal metabolism of cancer cells, thereby stopping the spread of cancer cells. The Company currently has two promising product candidates. One is VDA-1275, which combats solid tumours and has performed well in preclinical studies. The other is VDA-1102, an ointment for an early form of skin cancer that was already in a Phase 2a clinical trial.

    According to the announcement on January 2, this was successfully used in patients with a specific form of cutaneous T-cell lymphoma, Mycosis Fungoides. The study results show excellent values. The objective response rate was 56%, with 22% showing a complete response to the treatment. In 34% of the subjects, a partial response was observed in the first 12 weeks, with continued improvement noted by week 16. Disease progression was prevented in all participants. Compared to other treatments, VDA-1102 demonstrated a significantly faster effect. Based on these results, the pivotal Phase 2/3 study can now commence.

    In mid-December, Vidac Pharma received confirmation from the US Patent and Trademark Office that patent protection for the oncology drug candidates had been significantly extended. This now also applies to indications such as prostate, pancreatic, lung, cervical and colorectal cancer, as well as to dosage forms. The CEO expressed his delight: "The evidence that Vidac's two drug candidates have revolutionary potential for a variety of tumours is growing, and the extension of our US patent is confirmation that we are on the right track." The share price has increased by more than 250% since mid-August and has recently consolidated. Currently, a share costs EUR 0.70.

    BioNTech – Opportunity or risk?

    2025 is an important year for BioNTech. After the success of the COVID-19 vaccine, the Company is increasingly focusing on oncology. With mRNA-based therapies and bispecific antibodies, the Company aims to put cancer in its place. These approaches cover a large part of the pipeline. Meanwhile, a number of studies are underway, such as the Phase 3 study on small cell lung cancer, but individualised mRNA vaccines are also showing good progress. Initial research results from bowel and bladder cancer studies could be available as early as 2025 or 2026, raising new hopes for approval.

    All these parallel research projects cost a lot of money and cause high losses. After high profits during the pandemic, a net loss of more than EUR 700 million is expected for 2025. Declining revenues from COVID-19 vaccines are weighing on the figures, while research costs continue to rise. Nevertheless, BioNTech has enough funds to push projects forward. Analysts find the stock undervalued and see price targets of up to USD 137. A new high is likely if the Company makes a breakthrough in oncology.

    Nevertheless, the mRNA industry is highly competitive. Moderna and CureVac are also working on new therapies. However, BioNTech could offer advantages with a combination of mRNA technology and antibody therapies. The oncology pipeline is broadly diversified, and the first cancer drug is expected to come onto the market in 2026. Nevertheless, investors should take a look at what is happening in the US. With Robert F. Kennedy Jr. as the new US Secretary of Health, who has been highly critical of the COVID-19 vaccination campaign, potential lawsuits for damages against Pfizer could also eventually impact BioNTech. The share is currently trading at EUR 108.00.


    All three candidates have innovative cancer therapies in development. Although Evotec can score with innovative technologies and strategic partnerships, management is facing a realignment after weak business figures. Vidac Pharma has received positive feedback from the US Patent Office and recently presented strong Phase 2a study results. BioNTech has focused its efforts on mRNA-based cancer research. However, as expected, the Company's most recent figures were significantly weaker. The first oncology drug is expected to be on the market in 2026. In summary, cancer research is and remains a lucrative market.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Fabian Lorenz on February 13th, 2025 | 07:10 CET

    ACQUISITION?! Renk, BioNTech, and Biotech Highflyer Vidac Pharma

    • Biotechnology
    • Biotech
    • Defense

    Is Renk about to be taken over? Quite possible. The Company, known for its transmissions for the Leopard tank, has a new major shareholder. And it turns out to be none other than KNDS – the maker of the Leopard 2 tank. The Renk share price reacted with a jump of 10%. Is there more to come? Vidac Pharma is also frequently mentioned as a potential takeover candidate. Like BMW, the Company is working on a "new class". But in this case, it is to save human lives. To this end, last year's biotech highflyer aims to revolutionize cancer treatment. Experts believe that a multiplication of the share price is possible. BioNTech is also fighting cancer. In addition to its own research, the German company is strategically focusing on acquisitions. Another one has just been completed. What is next?

    Read

    Commented by Fabian Lorenz on February 12th, 2025 | 07:00 CET

    Analysts on the TUI CRASH! Bayer to make millions! dynaCERT stock is set to skyrocket!

    • Hydrogen
    • greenhydrogen
    • Travel
    • Pharma

    Will the dynaCERT stock see a breakthrough soon? The odds are looking good. In an analyst interview, the top German manager cites an increase in revenue, sales, and earnings as a clear goal for the next 12 months. In that case, the stock would currently be a bargain. The TUI share, however, does not appear to be a bargain for investors. The quarterly figures led to a sell-off yesterday. Yet revenue and earnings were in line with expectations. What do analysts say? Bayer's stock also trended weak yesterday, despite new potential millions in revenue from a drug approval.

    Read

    Commented by Fabian Lorenz on February 10th, 2025 | 07:30 CET

    BIOTECH stocks in RALLY MODE: Valneva, BioNxt Solutions, Evotec – BUY signal or correction?

    • Biotechnology
    • Biotech
    • Pharma

    After the 50% rally, the stock of BioNxt Solutions is currently consolidating. However, the next buy signal could be generated soon. There will likely be some exciting announcements this year and perhaps even a strategic partnership. The new R&D site in Munich will likely also attract attention for the innovative biotech company in Germany. After the catastrophic year, things have quieted down for the time being at Evotec. Or is it more that the air has been let out? After all, there is a lot of uncertainty about what skeletons might still be in the closet and how things should continue strategically. The stock market does not like that. In contrast, Valneva has had an impressive rally since mid-January. Last week, there was another big announcement. After 50%, is there more potential with the French company?

    Read